齐鲁晚报.齐鲁壹点周千清 12月4日，菏泽召开菏泽市"决胜'十四五'续写新篇章"系列主题新闻发布会(科技创新专场)，菏泽市科技局党组书记徐静、市科技局发展规划科科长张一 凡、市科技局资源配置与科研诚信科科长周溦、市科技局高新技术发展及产业化科科长杨红岩，共同介绍为大家介绍"十四五"时期菏泽市科技创新发展成 效，并回答记者关心的问题。 "十四五"以来，在市委市政府正确领导下，在全社会共同努力下，菏泽市深入实施创新驱动发展战略，大力推进科技创新与产业创新深度融合，全市科技 创新取得突破性进展，为经济社会高质量发展提供了有力支撑。 科技管理体制实现重大变革，科技发展统筹作用显著增强 紧跟党中央和省委部署，加强党对科技工作的统一领导，成立中共菏泽市委科技委员会，统筹安排、协调部署全市科技创新重大战略任务、重点发展规 划、重要政策举措，实现了市县之间联动运转，部门之间协同配合，形成了全市科技工作"一盘棋"的发展格局。 科技基础条件实现夯实优化，科技创新能力加快提升 科技创新成果丰硕，新质生产力蓬勃发展 一是高新技术产业发展迅速。2024年底，高新技术产业产值占规模以上工业总产值的比重超42%，较2020年提高4.27个 ...

Group 1 - The company announced the completion of business registration changes for its wholly-owned subsidiary, Yangling Buchang Pharmaceutical Co., Ltd. [1] - The changes include an updated business scope, which now encompasses traditional Chinese medicine extraction, medical research and development, and solar power technology services [1] - The registered capital of Yangling Buchang is 158 million RMB, and the company was established on August 31, 2010 [1] Group 2 - The company reported that its wholly-owned subsidiary, Baoding Tianhao Pharmaceutical Co., Ltd., has received approval from the Hebei Provincial Drug Administration for changes to its drug production license [3] - The changes include the addition of new production lines and workshops, specifically for soft capsule production and oral solution production lines [4][5] - The production license is valid until July 7, 2030, and the company is authorized to produce various forms of medications, including ointments, tablets, and oral solutions [4][5]

Core Insights - The flu positive rate in China has reached nearly 45%, indicating a significant rise in flu cases, with some provinces experiencing high epidemic levels [1] - Investors are closely monitoring the supply and sales of flu medications and vaccines from listed pharmaceutical companies, which are actively preparing to meet public health needs [1] Group 1: Drug and Vaccine Supply - Multiple listed companies have reported sufficient reserves of flu medications and vaccines, ensuring stable supply capabilities [2] - Renhe Pharmaceutical has initiated a priority supply mechanism for Oseltamivir, while Dajia Weikang has adjusted production capacity based on market demand [2] - The entire supply chain, including raw material suppliers like Rhine Bio, is collaborating to ensure a robust response to market needs [2] Group 2: Vaccine Development - Companies are focusing on flu vaccines as a key area for development, with several achieving significant progress by 2025 [3] - Zhejiang Tianyuan Biopharmaceutical's quadrivalent flu vaccine "Yufening" has been approved for sale, alongside its trivalent vaccine "Yuganning" [3] - Baike Bio has innovated with a freeze-dried nasal spray flu vaccine, which has been upgraded to a liquid form for easier administration [3] Group 3: Treatment Options - Companies are building a diverse matrix of flu medications to address various symptoms and treatment needs [5] - Zhongsheng Pharmaceutical is advancing the commercialization of Anladiwei tablets for treating uncomplicated influenza, while Jichuan Pharmaceutical is developing a novel flu treatment [5] - Oseltamivir remains a commonly used antiviral, with multiple companies like Renfu Pharmaceutical and Dajia Weikang actively involved in its production [5][6] Group 4: Symptomatic Relief - Several companies are providing symptomatic treatments for flu, including Lisheng Pharmaceutical's Acetaminophen and various products from Zhenbaodao for symptom relief [6] - Companies like Foci Pharmaceutical produce a range of cold and flu medications, ensuring comprehensive treatment options for patients [6]

Core Viewpoint - Company announced a change in the business scope of its wholly-owned subsidiary, Yangling Buchang Pharmaceutical Co., Ltd., to meet operational management needs [2] Group 1 - The fifth meeting of the fifth board of directors is scheduled for November 7, 2025, to review the proposal for the change in business scope [2] - Yangling Buchang has completed the industrial and commercial change registration procedures and obtained a new business license from the Yangling Demonstration Zone Market Supervision Administration [2]

关于全资子公司完成工商变更登记的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 证券代码：603858 证券简称：步长制药 公告编号：2025-226 山东步长制药股份有限公司 经营范围：一般项目：中药提取物生产；医学研究和试验发展；非居住房 地产租赁；太阳能发电技术服务(除依法须经批准的项目外，凭营业执照依法自 主开展经营活动)。许可项目：药品生产；药品委托生产；药品进出口；药品批 发(依法须经批准的项目，经相关部门批准后方可开展经营活动，具体经营项目 1 山东步长制药股份有限公司（以下简称"公司"）于 2025 年 11 月 7 日召开 第五届董事会第三十五次会议，审议通过了《关于全资子公司经营范围变更的议 案》，公司全资子公司杨凌步长制药有限公司（以下简称"杨凌步长"）因经营管 理之需要，拟对经营范围进行变更。具体内容详见公司 2025 年 11 月 8 日披露于 上海证券交易所网站（www.sse.com.cn）的《关于全资子公司经营范围变更的公 告》（公告编号：2025-209）。 近日，杨凌步长已完成工商变更 ...

证券代码：603858 证券简称：步长制药 公告编号：2025-227 山东步长制药股份有限公司 关于全资子公司药品生产许可证变更的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 山东步长制药股份有限公司（以下简称"公司"）近日获悉全资子公司保定 天浩制药有限公司（以下简称"保定天浩"）获得河北省药品监督管理局许可， 同意保定天浩《药品生产许可证》车间生产线、药品委托情况的变更，其他内容 不变，现将相关情况公告如下： 许可证编号：冀 20150057 一、药品生产许可证相关情况 企业名称：保定天浩制药有限公司 注册地址：河北省定兴县兴华东路 128 号 分类码：AhzBh 法定代表人：王益民 企业负责人：殷文忠 质量负责人：卢颖 生产地址和生产范围：河北省定兴县兴华东路 128 号：搽剂，软膏剂，片剂， 溶液剂（外用），乳膏剂，凝胶剂，灌肠剂，油剂，硬胶囊剂，颗粒剂，喷雾剂 （仅限注册申报使用）*** 山东省菏泽市中华西路 1668 号（山东步长神州制药有限公司）：集团内共 用中药提取、颗粒剂*** 1 山东步长制药股份 ...

Core Viewpoint - Company Baichang Pharmaceutical's subsidiary, Baoding Tianhao Pharmaceutical Co., Ltd., has received a renewed drug production license from the Hebei Provincial Drug Administration, allowing for changes in production lines and facilities, which is expected to positively impact the company's future operations [1] Group 1: License and Production Changes - The renewed drug production license includes the addition of a new workshop and production line located at 16 Bichang Road, Qindu District, Xianyang City, Shaanxi Province [1] - The new workshop is designated for soft capsule production, and the production line is for oral solution dosage forms, specifically Vitamin D drops [1] - The company has commissioned Shaanxi Baichang Pharmaceutical Co., Ltd. to produce Vitamin D drops with specific dosages, which currently do not have approval numbers [1] Group 2: Operational Impact - The changes in the drug production license are expected to optimize the company's production structure and maintain stable production capacity to meet market demand [1] - The license changes are anticipated to have a positive impact on the company's future operations [1]

Group 1 - Company provided a guarantee of 80 million RMB for its wholly-owned subsidiary, Shaanxi Buchang Pharmaceutical Co., Ltd., in a loan agreement with Huaxia Bank [2][7] - The board approved a total financing limit of up to 6.92 billion RMB for 2025, with specific guarantee limits for subsidiaries based on their debt ratios [3][12] - As of the announcement date, the total amount of guarantees provided by the company and its subsidiaries was 2.296 billion RMB, accounting for 22.48% of the company's audited net assets as of the end of 2024 [14] Group 2 - The company’s wholly-owned subsidiary, Shandong Danhong Pharmaceutical Co., Ltd., signed a contract with Beijing Excellent Future International Pharmaceutical Technology Development Co., Ltd. for clinical trials of a new drug [17] - The total cost for the clinical trial is 60.338 million RMB, covering 480 cases, with provisions for adjustments based on the final sample size [19] - This contract is expected to enhance the company's drug research and development capabilities, potentially saving time and costs in clinical trials [34] Group 3 - The company’s subsidiary, Shaanxi Buchang, received approval for changes to its drug production license, allowing for the addition of a new production line for tablets [42] - The changes are anticipated to optimize production structure and maintain stable production capacity to meet market demand [43]

Policy Developments - The State Council, led by Li Qiang, held a meeting to advance the provincial coordination of basic medical insurance [2] Medical Device Approvals - Yuhanglong received two medical device registration certificates for diagnostic kits related to primary biliary cholangitis and idiopathic membranous nephropathy, enhancing its product line in liver and kidney disease diagnostics [4] - Hengrui Medicine announced the approval of clinical trial notifications for five drugs, including the humanized anti-PD-L1 monoclonal antibody Abedilizumab, with total R&D investments amounting to approximately 1.1 billion yuan [5] Capital Market Activities - Mindray Medical's chairman, Li Xiting, plans to increase his stake in the company by 200 million yuan, having already purchased shares worth approximately 30 million yuan [7] - Huayu Pharmaceutical intends to establish a private equity fund focused on the biomedical sector, with an initial commitment of 150 million yuan from the company [8][9] Industry Milestones - The first brain-computer interface surgery in China was successfully completed, utilizing a device from Wuhan Zhonghua Brain-Machine Fusion Technology Co., with the procedure priced according to government regulations [11] Clinical Trials and Collaborations - Buchang Pharmaceutical's subsidiary signed a contract for clinical trials of a new product, with a total cost of approximately 60 million yuan, aimed at enhancing the company's drug development capabilities [12] - Jincheng Pharmaceutical terminated negotiations with Giskit Pharma B.V. regarding exclusive commercialization rights, with no financial impact expected [14]

Core Viewpoint - Company signed a contract for clinical trial services for a new product, indicating a strategic move to advance its product pipeline and enhance market competitiveness [1] Group 1: Contract Details - The contract is between the company's subsidiary, Shandong Danhong Pharmaceutical Co., Ltd., and Beijing Excellent Future International Pharmaceutical Technology Development Co., Ltd. for the clinical trial of "Shenfu Yixin Granules" [1] - The total cost for the clinical trial is 60,338,000.00 yuan (including tax), covering 480 cases with a 20% dropout rate [1] - If the final sample size exceeds 520 cases, additional costs will be calculated at 108,890.00 yuan per case, with a supplementary agreement to be signed [1] Group 2: Cost Breakdown - The total cost includes various expenses such as CRO service fees, hospital fees, data management and statistics, SMO fees, and recruitment costs [1]